PFM Health Sciences LP Has $8.16 Million Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

PFM Health Sciences LP boosted its stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 9.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 423,910 shares of the company’s stock after acquiring an additional 36,553 shares during the quarter. PFM Health Sciences LP owned 0.50% of Syndax Pharmaceuticals worth $8,160,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Eventide Asset Management LLC bought a new stake in shares of Syndax Pharmaceuticals during the third quarter worth $15,150,000. BNP Paribas Financial Markets grew its holdings in shares of Syndax Pharmaceuticals by 375.6% during the third quarter. BNP Paribas Financial Markets now owns 21,099 shares of the company’s stock worth $406,000 after purchasing an additional 16,663 shares during the last quarter. Propel Bio Management LLC grew its holdings in shares of Syndax Pharmaceuticals by 60.1% during the third quarter. Propel Bio Management LLC now owns 133,259 shares of the company’s stock worth $2,565,000 after purchasing an additional 50,000 shares during the last quarter. Quantbot Technologies LP bought a new stake in shares of Syndax Pharmaceuticals during the third quarter worth $49,000. Finally, FMR LLC grew its holdings in shares of Syndax Pharmaceuticals by 33.6% during the third quarter. FMR LLC now owns 49,248 shares of the company’s stock worth $948,000 after purchasing an additional 12,377 shares during the last quarter.

Analyst Ratings Changes

SNDX has been the topic of several recent research reports. Citigroup raised their price target on Syndax Pharmaceuticals from $37.00 to $45.00 and gave the company a “buy” rating in a report on Tuesday, November 19th. Barclays raised their price target on Syndax Pharmaceuticals from $32.00 to $33.00 and gave the company an “overweight” rating in a report on Thursday, August 15th. HC Wainwright raised their price target on Syndax Pharmaceuticals from $49.00 to $51.00 and gave the company a “buy” rating in a report on Monday, November 18th. StockNews.com cut Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, November 23rd. Finally, Stifel Nicolaus raised their price target on Syndax Pharmaceuticals from $40.00 to $41.00 and gave the company a “buy” rating in a report on Monday, October 14th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $37.64.

Syndax Pharmaceuticals Stock Performance

Shares of Syndax Pharmaceuticals stock opened at $16.72 on Friday. The business’s 50 day simple moving average is $18.44 and its 200 day simple moving average is $19.81. Syndax Pharmaceuticals, Inc. has a 52-week low of $15.00 and a 52-week high of $25.34. The firm has a market cap of $1.43 billion, a PE ratio of -4.61 and a beta of 0.92.

Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its earnings results on Tuesday, November 5th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.13) by $0.15. The firm had revenue of $12.50 million during the quarter, compared to analyst estimates of $9.16 million. During the same period in the prior year, the business posted ($0.73) EPS. As a group, equities research analysts predict that Syndax Pharmaceuticals, Inc. will post -2.39 EPS for the current year.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).